Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval
Set For First-In-Class Status
Executive Summary
Approved in the US in May, the drug is the latest targeted therapy to emerge from Lilly’s oncology division Loxo.
You may also be interested in...
LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer
Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.
4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.